Dyne Therapeutics, Inc.
DYN
$18.29
-$0.37-1.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.80% | 15.06% | 20.84% | 11.84% | 98.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.15% | 42.83% | 62.66% | 49.37% | 42.01% |
| Operating Income | -36.15% | -42.83% | -62.66% | -49.37% | -42.01% |
| Income Before Tax | -40.58% | -43.90% | -60.28% | -42.63% | -34.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.58% | -43.90% | -60.28% | -42.63% | -34.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.58% | -43.90% | -60.28% | -42.63% | -34.54% |
| EBIT | -36.15% | -42.83% | -62.66% | -49.37% | -42.01% |
| EBITDA | -36.21% | -42.94% | -62.93% | -49.62% | -42.30% |
| EPS Basic | -5.63% | -2.84% | -7.80% | 9.36% | 14.86% |
| Normalized Basic EPS | -5.63% | -2.84% | -7.79% | 9.36% | 14.86% |
| EPS Diluted | -5.63% | -2.84% | -7.80% | 9.36% | 14.86% |
| Normalized Diluted EPS | -5.63% | -2.84% | -7.79% | 9.36% | 14.86% |
| Average Basic Shares Outstanding | 36.34% | 39.23% | 44.11% | 53.88% | 57.72% |
| Average Diluted Shares Outstanding | 36.34% | 39.23% | 44.11% | 53.88% | 57.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |